Is Fortress Biotech, Inc. (FBIOP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 101.3% / 30% | 76.4% / 30% | 13.9% / 30% | 4.65% / 5% | ✗ NOT HALAL |
| DJIM | 101.3% / 33% | 76.4% / 33% | 13.9% / 33% | 4.65% / 5% | ✗ NOT HALAL |
| MSCI | 52.7% / 33% | 39.7% / 33% | 7.2% / 33% | 4.65% / 5% | ✗ NOT HALAL |
| S&P | 101.3% / 33% | 76.4% / 33% | 13.9% / 33% | 4.65% / 5% | ✗ NOT HALAL |
| FTSE | 52.7% / 33% | 39.7% / 33% | 7.2% / 50% | 4.65% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 32.0% | |
| Operating Margin | -38.6% | |
| Net Margin | 6.4% | |
| Return on Equity (ROE) | -205.3% | |
| Return on Assets (ROA) | -34.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$80M |
| Free Cash Flow | -$95M |
| Total Debt | $76M |
| Debt-to-Equity | 104.8 |
| Current Ratio | 2.2 |
| Total Assets | $144M |
Price & Trading
| Last Close | $13.48 |
| 50-Day MA | $12.81 |
| 200-Day MA | $9.19 |
| Avg Volume | 26K |
| Beta | 1.4 |
|
52-Week Range
$4.72
| |
About Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Fortress Biotech, Inc. (FBIOP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Fortress Biotech, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Fortress Biotech, Inc.'s debt ratio?
Fortress Biotech, Inc.'s debt ratio is 101.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 52.7%.
What are Fortress Biotech, Inc.'s key financial metrics?
Fortress Biotech, Inc. has a market capitalization of $72M, and revenue of $58M. The company maintains a gross margin of 32.0% and a net margin of 6.4%. Return on equity stands at -205.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.